Key result
Second-generation drug-eluting stents feature significant methodological and technical improvements in platform, polymer, and drug components compared to earlier generation devices.
Why the study?
Do novel drug-eluting stents improve outcomes compared to earlier generation DES in patients undergoing coronary revascularization?
Do novel drug-eluting stents improve outcomes compared to earlier generation DES in patients undergoing coronary revascularization?
Answers are grounded in this paper and cite their sources.
This review summarizes the methodological and technical achievements of second-generation drug-eluting stents and their clinical evidence in coronary revascularization.
Due to safety concerns in recent years, much effort has been devoted to improving the outcomes associated with drug-eluting stents (DESs). This review summarizes the current status of methodological and technical achievements reported in second-generation DES. Novel stents are described based on the component (the platform, the polymer, and the drug) that has undergone the most significant changes compared to earlier generation DES. An overview of the currently available evidence on the use of novel coronary devices in patients undergoing coronary revascularization is also reviewed.
No takes yet. Share an insight, caveat, or question.
Tamburino et al. (2011) conducted a review in de novo coronary lesions. Second-generation drug-eluting stents vs. Earlier generation drug-eluting stents was evaluated. Second-generation drug-eluting stents feature significant methodological and technical improvements in platform, polymer, and drug components compared to earlier generation devices.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: